Comparison 8. Secondary outcome ‐ PASI 75 at 52 weeks.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
8.1 Biologic 1 versus biologic 2	16	8245	Risk Ratio (M‐H, Random, 95% CI)	1.09 [1.02, 1.16]
8.1.1 Secukinumab versus ustekinumab	2	1778	Risk Ratio (M‐H, Random, 95% CI)	1.13 [1.04, 1.22]
8.1.2 Risankizumab versus ustekinumab	2	799	Risk Ratio (M‐H, Random, 95% CI)	1.26 [1.12, 1.41]
8.1.3 Ixekizumab versus ustekinumab	1	302	Risk Ratio (M‐H, Random, 95% CI)	1.16 [1.05, 1.29]
8.1.4 Risankizumab versus secukinumab	1	327	Risk Ratio (M‐H, Random, 95% CI)	1.28 [1.14, 1.44]
8.1.5 Bimekizumab versus secukinumab	1	743	Risk Ratio (M‐H, Random, 95% CI)	1.09 [1.02, 1.16]
8.1.6 Guselkumab versus secukinumab	1	1048	Risk Ratio (M‐H, Random, 95% CI)	1.06 [1.00, 1.12]
8.1.7 Guselkumab versus adalimumab	1	663	Risk Ratio (M‐H, Random, 95% CI)	1.40 [1.28, 1.54]
8.1.8 Ixekizumab versus adalimumab	1	100	Risk Ratio (M‐H, Random, 95% CI)	1.07 [0.89, 1.27]
8.1.9 Secukinumab 150 versus secukinumab 300	3	1017	Risk Ratio (M‐H, Random, 95% CI)	0.90 [0.85, 0.94]
8.1.10 Guselkumab 100 versus guselkumab 50	1	128	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.88, 1.09]
8.1.11 Ixekizumab Q2W versus ixekizumab Q4W	1	1227	Risk Ratio (M‐H, Random, 95% CI)	1.14 [1.07, 1.22]
8.1.12 Risankizumab 75 versus risankizumab 150	1	113	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.91, 1.07]
8.2 Small molecule 1 versus small molecule 2	1	170	Risk Ratio (M‐H, Random, 95% CI)	1.12 [0.46, 2.78]
8.2.1 Apremilast 30 versus apremilast other	1	170	Risk Ratio (M‐H, Random, 95% CI)	1.12 [0.46, 2.78]